Following UK Chancellor of the Exchequer George Osborne’s confirmation of an overhaul of the Patent Box regime just last month, Financial Secretary to the Treasury, David Gauke, has provided much-needed clarity as to the timescales involved as part of a series of announcements made in the run up to this week’s Autumn Statement.
Commenting on the issue, Michael Jaeger, patent attorney at Withers & Rogers, said:“It has been confirmed that a new Patent Box regime is to be introduced in 2015 but that, crucially, this will be based on a comprehensive round of consultation with Patent Box users. This provides a platform for helping shape the new system, as well as a facility for determining whether individual businesses still qualify.”
He noted that Mr Gauke “has specifically pledged a commitment to encouraging more British businesses to perform their R&D in the UK. For those already doing this, the proposals should not affect their ability to benefit from Patent Box. In particular, where 77% or more of the R&D work for a patented invention is undertaken in the UK, a company can benefit fully from patent box. Where the amount of UK-based R&D undertaken is less than this amount, the extent to which the company can benefit will be reduced accordingly.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze